Senate Panel Passes Breakthrough Device, Other Measures; FDA Funding Debated
This article was originally published in Clinica
The Senate Health, Education, Labor and Pensions Committee passed breakthrough medical device legislation, as well as combination products and digital health regulatory reform bills, on March 9 as part of the panel's effort to pass a broad-reaching biomedical innovation package this year.
You may also be interested in...
Industry Gives Big Money To GOP Senators Backing Device Reforms, But Buys Into Clinton Over Trump, 14-1
In the 2016 election race, the most generous device and diagnostic industry contributors donated heavily to Senate Republicans giving legislative attention to FDA regulatory reforms – Richard Burr, N.C., Kelly Ayotte, N.H., Pat Toomey, Pa. – running close races against Democrat challengers. But while industry primarily backs GOP senators, they also favor Hillary Clinton (D) over Donald Trump (R) with their donations, 14-1.
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”
CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.